In this study, we aimed to investigate the therapeutic implications of ACMSD inhibition in the treatment of metabolic dysfunction-associated steatotic liver disease/steatohepatitis (MASLD/MASH). Here, ACMSD is linked to metabolic dysfunction-associated steatotic liver disease.